Nov 19th, 2015
Why Inversion Deals Are All the Rage in the Pharma Industry
Marshall Sonenshine, Sonenshine Partners chairman, comments on Pfizer possibly being in advanced talks to buy Allergan for as much as $380 per share. He speaks with Bloomberg's Betty Liu on "Bloomberg Markets." (Source: Bloomberg)
